Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Sun, May 25, 2025
[Archive]
Volume 1, Issue 1 (1-2010)
Caspian J Intern Med 2010, 1(1): 9-11 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Aghamohammadzadeh N, Tabrizi A, Niafar M, Najafipor F. Efficacy of adding glutazone to the maximum dose of glibenclamide and metformin resistant on type 2 diabetic patients. Caspian J Intern Med 2010; 1 (1) :9-11
URL: http://caspjim.com/article-1-62-en.html
URL: http://caspjim.com/article-1-62-en.html
Abstract: (10982 Views)
Background: To evaluate the efficacy of adding the glutazone to maximum dose of sulfonylurea and metformin in patients with poorly controlled type 2 diabetes.
Methods: Ninety six patients with type 2 diabetes who had failed medical therapy with maximal-dosage of metformin and glibenclamide received glutazone. Fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C, cholesterol and HDL levels were assessed at baseline three months later.
Results: Ninety-six patients with type 2 diabetes (74 women and 22 men) with the mean age of 55.7±9.9 years were studied. Significant reduction was seen in fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C and triglyceride levels three months after adding glutazone to therapeutic regimen (p<0.0005). There was not a significant rise in cholesterol and HDL levels before and after the new therapy.
Conclusion: The results show that the combination of glutazone, metformin and glibenclamide may result in better control of glycemic status in diabetic patients resistant to oral first-line agents.
Methods: Ninety six patients with type 2 diabetes who had failed medical therapy with maximal-dosage of metformin and glibenclamide received glutazone. Fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C, cholesterol and HDL levels were assessed at baseline three months later.
Results: Ninety-six patients with type 2 diabetes (74 women and 22 men) with the mean age of 55.7±9.9 years were studied. Significant reduction was seen in fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C and triglyceride levels three months after adding glutazone to therapeutic regimen (p<0.0005). There was not a significant rise in cholesterol and HDL levels before and after the new therapy.
Conclusion: The results show that the combination of glutazone, metformin and glibenclamide may result in better control of glycemic status in diabetic patients resistant to oral first-line agents.
Type of Study: Original Article |
Subject:
Infectious Diseases
Received: 2014/01/14 | Accepted: 2014/01/14 | Published: 2014/01/14
Received: 2014/01/14 | Accepted: 2014/01/14 | Published: 2014/01/14
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
